<?xml version='1.0' encoding='utf-8'?>
<document id="23497760"><sentence text="Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers."><entity charOffset="58-71" id="DDI-PubMed.23497760.s1.e0" text="empagliflozin" /><entity charOffset="75-89" id="DDI-PubMed.23497760.s1.e1" text="sodium glucose" /><entity charOffset="121-130" id="DDI-PubMed.23497760.s1.e2" text="verapamil" /><entity charOffset="132-140" id="DDI-PubMed.23497760.s1.e3" text="ramipril" /><entity charOffset="145-152" id="DDI-PubMed.23497760.s1.e4" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e0" e2="DDI-PubMed.23497760.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e0" e2="DDI-PubMed.23497760.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e0" e2="DDI-PubMed.23497760.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e0" e2="DDI-PubMed.23497760.s1.e3" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e0" e2="DDI-PubMed.23497760.s1.e4" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e1" e2="DDI-PubMed.23497760.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e1" e2="DDI-PubMed.23497760.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e1" e2="DDI-PubMed.23497760.s1.e3" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e1" e2="DDI-PubMed.23497760.s1.e4" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e2" e2="DDI-PubMed.23497760.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e2" e2="DDI-PubMed.23497760.s1.e3" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e2" e2="DDI-PubMed.23497760.s1.e4" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e3" e2="DDI-PubMed.23497760.s1.e3" /><pair ddi="false" e1="DDI-PubMed.23497760.s1.e3" e2="DDI-PubMed.23497760.s1.e4" /></sentence><sentence text="Empagliflozin is a sodium glucose cotransporter 2 inhibitor in clinical development as a treatment for type 2 diabetes mellitus"><entity charOffset="0-13" id="DDI-PubMed.23497760.s2.e0" text="Empagliflozin" /><entity charOffset="19-33" id="DDI-PubMed.23497760.s2.e1" text="sodium glucose" /><pair ddi="false" e1="DDI-PubMed.23497760.s2.e0" e2="DDI-PubMed.23497760.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23497760.s2.e0" e2="DDI-PubMed.23497760.s2.e1" /></sentence><sentence text="" /><sentence text="The goal of this study was to investigate potential drug-drug interactions between empagliflozin and verapamil, ramipril, and digoxin in healthy volunteers"><entity charOffset="83-96" id="DDI-PubMed.23497760.s4.e0" text="empagliflozin" /><entity charOffset="101-110" id="DDI-PubMed.23497760.s4.e1" text="verapamil" /><entity charOffset="112-120" id="DDI-PubMed.23497760.s4.e2" text="ramipril" /><entity charOffset="126-133" id="DDI-PubMed.23497760.s4.e3" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.23497760.s4.e0" e2="DDI-PubMed.23497760.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23497760.s4.e0" e2="DDI-PubMed.23497760.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23497760.s4.e0" e2="DDI-PubMed.23497760.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23497760.s4.e0" e2="DDI-PubMed.23497760.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23497760.s4.e1" e2="DDI-PubMed.23497760.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23497760.s4.e1" e2="DDI-PubMed.23497760.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23497760.s4.e1" e2="DDI-PubMed.23497760.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23497760.s4.e2" e2="DDI-PubMed.23497760.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23497760.s4.e2" e2="DDI-PubMed.23497760.s4.e3" /></sentence><sentence text="" /><sentence text="The potential drug-drug interactions were evaluated in 3 separate trials" /><sentence text=" In the first study, 16 subjects were randomized to receive single-dose empagliflozin 25 mg alone or single-dose empagliflozin 25 mg with single-dose verapamil 120 mg"><entity charOffset="72-85" id="DDI-PubMed.23497760.s7.e0" text="empagliflozin" /><entity charOffset="113-126" id="DDI-PubMed.23497760.s7.e1" text="empagliflozin" /><pair ddi="false" e1="DDI-PubMed.23497760.s7.e0" e2="DDI-PubMed.23497760.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23497760.s7.e0" e2="DDI-PubMed.23497760.s7.e1" /></sentence><sentence text=" In the second study, 23 subjects were randomized to receive empagliflozin 25 mg once daily (QD) for 5 days, ramipril (2"><entity charOffset="61-74" id="DDI-PubMed.23497760.s8.e0" text="empagliflozin" /><entity charOffset="109-117" id="DDI-PubMed.23497760.s8.e1" text="ramipril" /><pair ddi="false" e1="DDI-PubMed.23497760.s8.e0" e2="DDI-PubMed.23497760.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23497760.s8.e0" e2="DDI-PubMed.23497760.s8.e1" /></sentence><sentence text="5 mg on day 1 then 5 mg QD on days 2-5) for 5 days or empagliflozin 25 mg with ramipril (2"><entity charOffset="54-67" id="DDI-PubMed.23497760.s9.e0" text="empagliflozin" /><entity charOffset="79-87" id="DDI-PubMed.23497760.s9.e1" text="ramipril" /><pair ddi="false" e1="DDI-PubMed.23497760.s9.e0" e2="DDI-PubMed.23497760.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23497760.s9.e0" e2="DDI-PubMed.23497760.s9.e1" /></sentence><sentence text="5 mg on day 1 then 5 mg QD on days 2-5) for 5 days" /><sentence text=" In the third study, 20 subjects were randomized to receive single-dose digoxin 0"><entity charOffset="72-79" id="DDI-PubMed.23497760.s11.e0" text="digoxin" /></sentence><sentence text="5 mg alone or empagliflozin 25 mg QD for 8 days with single-dose digoxin 0"><entity charOffset="14-27" id="DDI-PubMed.23497760.s12.e0" text="empagliflozin" /><entity charOffset="65-72" id="DDI-PubMed.23497760.s12.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.23497760.s12.e0" e2="DDI-PubMed.23497760.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23497760.s12.e0" e2="DDI-PubMed.23497760.s12.e1" /></sentence><sentence text="5 mg on day 5" /><sentence text="" /><sentence text="Exposure of empagliflozin was not affected by coadministration with verapamil (AUC0-∞: geometric mean ratio [GMR], 102"><entity charOffset="12-25" id="DDI-PubMed.23497760.s15.e0" text="empagliflozin" /><entity charOffset="68-77" id="DDI-PubMed.23497760.s15.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.23497760.s15.e0" e2="DDI-PubMed.23497760.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23497760.s15.e0" e2="DDI-PubMed.23497760.s15.e1" /></sentence><sentence text="95%; 90% CI, 98"><entity charOffset="9-11" id="DDI-PubMed.23497760.s16.e0" text="CI" /></sentence><sentence text="87-107" /><sentence text="20; Cmax: GMR, 92" /><sentence text="39%; 90% CI, 85"><entity charOffset="9-11" id="DDI-PubMed.23497760.s19.e0" text="CI" /></sentence><sentence text="38-99" /><sentence text="97) or ramipril (AUC over a uniform dosing interval τ at steady state [AUCτ,ss]: GMR, 96"><entity charOffset="7-15" id="DDI-PubMed.23497760.s21.e0" text="ramipril" /></sentence><sentence text="55%; 90% CI, 93"><entity charOffset="9-11" id="DDI-PubMed.23497760.s22.e0" text="CI" /></sentence><sentence text="05-100" /><sentence text="18; Cmax at steady state [Cmax,ss]: GMR, 104" /><sentence text="47%; 90% CI 97"><entity charOffset="9-10" id="DDI-PubMed.23497760.s25.e0" text="CI" /></sentence><sentence text="65-111" /><sentence text="77)" /><sentence text=" Empagliflozin had no clinically relevant effect on exposure of ramipril (AUCτ,ss: GMR, 108"><entity charOffset="1-14" id="DDI-PubMed.23497760.s28.e0" text="Empagliflozin" /><entity charOffset="64-72" id="DDI-PubMed.23497760.s28.e1" text="ramipril" /><entity charOffset="74-78" id="DDI-PubMed.23497760.s28.e2" text="AUCτ" /><entity charOffset="83-86" id="DDI-PubMed.23497760.s28.e3" text="GMR" /><pair ddi="false" e1="DDI-PubMed.23497760.s28.e0" e2="DDI-PubMed.23497760.s28.e0" /><pair ddi="false" e1="DDI-PubMed.23497760.s28.e0" e2="DDI-PubMed.23497760.s28.e1" /><pair ddi="false" e1="DDI-PubMed.23497760.s28.e0" e2="DDI-PubMed.23497760.s28.e2" /><pair ddi="false" e1="DDI-PubMed.23497760.s28.e0" e2="DDI-PubMed.23497760.s28.e3" /><pair ddi="false" e1="DDI-PubMed.23497760.s28.e1" e2="DDI-PubMed.23497760.s28.e1" /><pair ddi="false" e1="DDI-PubMed.23497760.s28.e1" e2="DDI-PubMed.23497760.s28.e2" /><pair ddi="false" e1="DDI-PubMed.23497760.s28.e1" e2="DDI-PubMed.23497760.s28.e3" /><pair ddi="false" e1="DDI-PubMed.23497760.s28.e2" e2="DDI-PubMed.23497760.s28.e2" /><pair ddi="false" e1="DDI-PubMed.23497760.s28.e2" e2="DDI-PubMed.23497760.s28.e3" /></sentence><sentence text="14%; 90% CI 100"><entity charOffset="9-11" id="DDI-PubMed.23497760.s29.e0" text="CI" /></sentence><sentence text="51-116" /><sentence text="35; Cmax,ss: GMR, 103"><entity charOffset="13-14" id="DDI-PubMed.23497760.s31.e0" text="GMR" /></sentence><sentence text="61%; 90% CI, 89"><entity charOffset="9-11" id="DDI-PubMed.23497760.s32.e0" text="CI" /></sentence><sentence text="73-119" /><sentence text="64) or its active metabolite ramiprilat (AUCτ,ss: GMR, 98"><entity charOffset="41-42" id="DDI-PubMed.23497760.s34.e0" text="AUCτ" /><entity charOffset="50-51" id="DDI-PubMed.23497760.s34.e1" text="GMR" /><pair ddi="false" e1="DDI-PubMed.23497760.s34.e0" e2="DDI-PubMed.23497760.s34.e0" /><pair ddi="false" e1="DDI-PubMed.23497760.s34.e0" e2="DDI-PubMed.23497760.s34.e1" /></sentence><sentence text="67%; 90% CI, 96"><entity charOffset="9-11" id="DDI-PubMed.23497760.s35.e0" text="CI" /></sentence><sentence text="00-101" /><sentence text="42; Cmax,ss: GMR, 98"><entity charOffset="13-14" id="DDI-PubMed.23497760.s37.e0" text="GMR" /></sentence><sentence text="29%; 90% CI, 92"><entity charOffset="9-11" id="DDI-PubMed.23497760.s38.e0" text="CI" /></sentence><sentence text="67-104" /><sentence text="25)" /><sentence text=" Coadministration of empagliflozin had no clinically meaningful effect on digoxin AUC0-∞ (GMR, 106"><entity charOffset="21-34" id="DDI-PubMed.23497760.s41.e0" text="empagliflozin" /><entity charOffset="90-102" id="DDI-PubMed.23497760.s41.e1" text="GMR" /><pair ddi="false" e1="DDI-PubMed.23497760.s41.e0" e2="DDI-PubMed.23497760.s41.e0" /><pair ddi="false" e1="DDI-PubMed.23497760.s41.e0" e2="DDI-PubMed.23497760.s41.e1" /></sentence><sentence text="11%; 90% CI, 96"><entity charOffset="9-11" id="DDI-PubMed.23497760.s42.e0" text="CI" /></sentence><sentence text="71-116" /><sentence text="41); however, a slight increase in Cmax was observed that was not considered clinically relevant (GMR, 113"><entity charOffset="98-99" id="DDI-PubMed.23497760.s44.e0" text="GMR" /></sentence><sentence text="94%; 90% CI, 99"><entity charOffset="9-11" id="DDI-PubMed.23497760.s45.e0" text="CI" /></sentence><sentence text="33-130" /><sentence text="70)" /><sentence text=" All treatments were well tolerated" /><sentence text=" There were no serious adverse events or adverse events leading to discontinuation in any of the studies" /><sentence text="" /><sentence text="No dose adjustment of empagliflozin is required when coadministered with ramipril or verapamil, and no dose adjustment of digoxin or ramipril is required when coadministered with empagliflozin"><entity charOffset="22-35" id="DDI-PubMed.23497760.s51.e0" text="empagliflozin" /><entity charOffset="73-81" id="DDI-PubMed.23497760.s51.e1" text="ramipril" /><entity charOffset="85-94" id="DDI-PubMed.23497760.s51.e2" text="verapamil" /><entity charOffset="122-129" id="DDI-PubMed.23497760.s51.e3" text="digoxin" /><entity charOffset="133-141" id="DDI-PubMed.23497760.s51.e4" text="ramipril" /><entity charOffset="179-192" id="DDI-PubMed.23497760.s51.e5" text="empagliflozin" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e0" e2="DDI-PubMed.23497760.s51.e0" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e0" e2="DDI-PubMed.23497760.s51.e1" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e0" e2="DDI-PubMed.23497760.s51.e2" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e0" e2="DDI-PubMed.23497760.s51.e3" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e0" e2="DDI-PubMed.23497760.s51.e4" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e0" e2="DDI-PubMed.23497760.s51.e5" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e1" e2="DDI-PubMed.23497760.s51.e1" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e1" e2="DDI-PubMed.23497760.s51.e2" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e1" e2="DDI-PubMed.23497760.s51.e3" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e1" e2="DDI-PubMed.23497760.s51.e4" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e1" e2="DDI-PubMed.23497760.s51.e5" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e2" e2="DDI-PubMed.23497760.s51.e2" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e2" e2="DDI-PubMed.23497760.s51.e3" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e2" e2="DDI-PubMed.23497760.s51.e4" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e2" e2="DDI-PubMed.23497760.s51.e5" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e3" e2="DDI-PubMed.23497760.s51.e3" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e3" e2="DDI-PubMed.23497760.s51.e4" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e3" e2="DDI-PubMed.23497760.s51.e5" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e4" e2="DDI-PubMed.23497760.s51.e4" /><pair ddi="false" e1="DDI-PubMed.23497760.s51.e4" e2="DDI-PubMed.23497760.s51.e5" /></sentence><sentence text=" ClinicalTrials" /><sentence text="gov identifiers: NCT01306175 (digoxin), NCT01276301 (verapamil), and NCT01284621 (ramipril)"><entity charOffset="53-62" id="DDI-PubMed.23497760.s53.e0" text="verapamil" /><entity charOffset="82-90" id="DDI-PubMed.23497760.s53.e1" text="ramipril" /><pair ddi="false" e1="DDI-PubMed.23497760.s53.e0" e2="DDI-PubMed.23497760.s53.e0" /><pair ddi="false" e1="DDI-PubMed.23497760.s53.e0" e2="DDI-PubMed.23497760.s53.e1" /></sentence><sentence text="" /></document>